Literature DB >> 17266030

Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse.

Gresin O Pizarro1, Xun Clare Zhou, Anthony Koch, Mahmood Gharib, Sejal Raval, Keith Bible, Monica B Jones.   

Abstract

The granulin-epithelin precursor (GEP/PCDGF), a 68-88 kDa secreted glycoprotein, has been shown to be an important growth and survival factor for ovarian cancer cells. Furthermore, GEP expression is a predictor of patient survival in metastatic ovarian cancer cells. Up to this point, however, the molecular mechanisms and clinical relevance of a GEP-mediated prosurvival phenotype remain poorly characterized. We hypothesize that the prosurvival function of GEP is important in ovarian cancer tumor progression and chemoresponse. To explore this hypothesis, we examined the effects of GEP overexpression on migration, invasion and cisplatin (CDDP) chemosensitivity in the ovarian cancer cell line A2780. Full length GEP transfectants demonstrated an increased capacity to migrate and invade their substratum when compared to empty vector controls. In addition, GEP overexpression was associated with CDDP chemoresistance. Finally, GEP overexpression increased tumor formation and protected cells from tumor regression in response to CDDP treatment in vivo. Taken together, these data support a role for GEP in tumor progression and development of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266030     DOI: 10.1002/ijc.22559

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

Review 1.  Progranulin: a growth factor, a novel TNFR ligand and a drug target.

Authors:  Chuan-ju Liu; Xavier Bosch
Journal:  Pharmacol Ther       Date:  2011-10-08       Impact factor: 12.310

Review 2.  Cellular effects of progranulin in health and disease.

Authors:  Louis De Muynck; Philip Van Damme
Journal:  J Mol Neurosci       Date:  2011-05-25       Impact factor: 3.444

Review 3.  Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases.

Authors:  Yazhou Cui; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2019-01-30       Impact factor: 7.638

Review 4.  Progranulin and its biological effects in cancer.

Authors:  Fabian Arechavaleta-Velasco; Carlos Eduardo Perez-Juarez; George L Gerton; Laura Diaz-Cueto
Journal:  Med Oncol       Date:  2017-11-07       Impact factor: 3.064

5.  Progranulin A-mediated MET signaling is essential for liver morphogenesis in zebrafish.

Authors:  Yen-Hsing Li; Mark Hung-Chih Chen; Hong-Yi Gong; Shao-Yang Hu; Ya-Wen Li; Gen-Hwa Lin; Ching-Chun Lin; Wangta Liu; Jen-Leih Wu
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

Review 6.  Structure, function, and mechanism of progranulin; the brain and beyond.

Authors:  Huishi Toh; Babykumari P Chitramuthu; Hugh P J Bennett; Andrew Bateman
Journal:  J Mol Neurosci       Date:  2011-06-21       Impact factor: 3.444

7.  Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.

Authors:  Jasmine J Han; Minshu Yu; Nicole Houston; Seth M Steinberg; Elise C Kohn
Journal:  Gynecol Oncol       Date:  2010-10-15       Impact factor: 5.482

8.  GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinoma.

Authors:  Martin J Edelman; Josephine Feliciano; Binbin Yue; Pablo Bejarano; Olga Ioffe; David Reisman; Douglas Hawkins; Qiwei Gai; David Hicks; Ginette Serrero
Journal:  Hum Pathol       Date:  2014-06-05       Impact factor: 3.466

9.  Lysosomal Dysfunction and Other Pathomechanisms in FTLD: Evidence from Progranulin Genetics and Biology.

Authors:  Xiaolai Zhou; Thomas Kukar; Rosa Rademakers
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration.

Authors:  Rupa Guha; Binbin Yue; Jianping Dong; Aditi Banerjee; Ginette Serrero
Journal:  Breast Cancer Res Treat       Date:  2021-02-22       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.